A I Schafer, … , S E Rittenhouse, E W Salzman Studies have been performed on the biochemical mechanism of platelet activation induced by the fibrinolytic protease plasmin. In washed human platelets, greater than or equal to 1.0 caseinolytic units (CU/ml plasmin induced aggregation. Platelet [14C]serotonin release was stimulated by 1.0 CU/ml plasmin to an extent comparable to that induced by 1.0 U/ml thrombin. A dose-and time-dependent phosphorylation of the platelet 47,000-and 20,000-kD proteins was noted in 32PO4-labeled platelets incubated with plasmin; phosphorylation was not affected by extracellular Ca2+, but was completely inhibited by an increase in platelet cyclic AMP. Phosphorylation of these platelet proteins suggested that plasmin may act on platelets by stimulating a rise in cytosolic calcium concentration ([Cai2+]) and activating inositol phospholipid-dependent phospholipase C and protein kinase C. Using both quin2 fluorescence and aequorin luminescence as indicators, plasmin was found to elevate platelet [Cai2+] 
Introduction
Plasmin is the protease of the fibrinolytic system that is formed by the proteolytic action of plasminogen activators on the circulating zymogen plasminogen (1) . Important interactions have been reported between plasmin and platelets, with which fibrin forms the hemostatic plug. Treatment of platelets with plasmin in vitro leads to the loss of platelet membrane glycoprotein Ib, a surface receptor for von Willebrand's factor (2) . We have recently shown that incubation of platelets with plasmin at con-centration; CTA, Committee on Thrombolytic Agents; CU, caseinolytic units; DAG, 1,2-diacylglycerol; DG, diglyceride; IP3, intracellular myplatelet shape change, aggregation or release, results in the doseand time-dependent inhibition of platelet aggregation and thromboxane A2 production in response to thrombin, collagen and calcium ionophore A23187 and the thrombin-induced release of [3H]arachidonic acid from membrane phospholipids, although exogenous arachidonate-stimulated aggregation and thromboxane generation were not blocked by preincubation with plasmin (3) . We now report that at higher concentrations, plasmin acts as a platelet agonist, stimulating rather than inhibiting platelet responsiveness.
The mechanism of surface signal transduction in platelets and other cells has been the subject of several recent reviews (4, 5) . Platelet activation by various extracellular signals is mediated by an increase in the cytosolic Ca2`concentration ([Ca, 2+] ). The mechanism of cellular response may involve a calmodulin-dependent activation of myosin light chain kinase, which leads to phosphorylation of the -20,000-kD light chains of myosin. In addition, a variety of biologically active substances exert their effects on platelets by interactions with specific cell surface receptors that induce the turnover of plasma membrane inositol phospholipids. The agonist-mediated breakdown of phosphatidylinositol 4,5-bisphosphate (PIP2) by phospholipase C generates two intracellular "messengers": myoinositol 1,4,5-triphosphate (UP3), which causes intracellular Ca2+ mobilization, and 1,2-diacylglycerol (DAG), which activates protein kinase C to phosphorylate an endogenous platelet protein of -47,000 kD. Maximal biologic effect has been considered to result from the synergistic actions of Ca2+ mobilization and receptor-linked inositol phospholipid breakdown and protein kinase C activation. In platelets, free arachidonic acid is produced from inositol phospholipids through consecutive reactions catalyzed by phospholipase C and diacylglycerol lipase. After conversion of DAG to phosphatidic acid, a specific phosphatidic acid lipase can also release free arachidonic acid. Furthermore, arachidonic acid can be hydrolyzed from phosphatidylcholine and phosphatidylethanolamine by phospholipase A2. Free arachidonic acid is rapidly oxygenated to a variety of biologically active eicosanoids, including thromboxane A2, a potent inducer ofplatelet aggregation and vasoconstrictor.
We now report that plasmin causes platelet aggregation and secretion, which are associated with phosphorylation ofboth the 20,000-and 47,000-kD proteins, calcium mobilization, and phospholipase C activation.
Methods
Plasmin preparation. Plasmin was dissolved in 10 mM Tris, 150 mM NaCl, pH 7.4, and stored in aliquots at -400C. CU were defined according oinositol 1,4,5-triphosphate; PA, phosphatidic acid; PAGE, polyacrylamide gel electrophoresis; PGE,, prostaglandin E,; PIP2, phosphatidylinositol 4,5-biphosphate; PRP, platelet-rich plasma; TLC, thin-layer chromatography; TXA2, TXB2, thromboxane A2 or B2.
to Sgouris et al. (6) : 1 CU equals 1.14 CTA (Committee on Thrombolytic Agents) units (7) . Plasmin activity was determined in an S-2288 chromogenic substrate assay following the manufacturer's method (8) . The assay was performed at 37°C in a spectrophotometer equipped with a recording chart (Gilford 2400, Gilford Instruments, Oberlin, OH). Kinetic data supplied by the manufacturer indicate that, for a substrate concentration of 1 X 10-3 mol/liter and a plasmin concentration of 4 X i0O-mol/liter, AA/min at 405 nm is 0.042. 1 CU plasmin = -0.45 nmol plasmin.
Human plasmin subjected to 10% sodium dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis (PAGE) produced two major bands with apparent molecular masses of 70,000 and 28,000 under reducing conditions, and a single band with an apparent molecular mass of81,000 under nonreducing conditions. Platelet aggregation. Venous blood anticoagulated with 13 mM sodium citrate was obtained from volunteers who had not ingested aspirin or other medications known to interfere with platelet function for at least 10 d prior to donation. Blood was centrifuged at 160 g for 10 min to obtain platelet-rich plasma (PRP). Platelets were separated from plasma by gel filtration by applying PRP to a column of Sepharose 2B. The platelets were eluted with a modified Tyrode's buffer containing 130 mM NaCl, 9 mM sodium bicarbonate, 6 mM dextrose, 10 mM sodium citrate, 10 mM Trizma base, 0.8 mM KH2PO4, 3 mM KCI, 0.9 mM MgCl2, and 0.5% albumin (for aggregation experiments), pH 7.3. Platelet counts were determined in a model F Coulter Counter (Coulter Electronics, Inc., Hialeah, FL). Aliquots of 0.4 ml of gel-filtered platelets were added to cuvettes containing CaCl2 (3 mM, final concentration). Aggregation was monitored using a standard nephelometric method (9) in a Payton dual-channel aggregometer (Payton Associates, Inc., Buffalo, NY Platelet 32PO4 labeling. Venous blood anticoagulated with 13.5% acid citrate dextrose (National Institutes of Health Formula A) containing 0.1 gM PGE, (final concentration) was centrifuged at 160 g for 10 min to obtain PRP. The separated PRP was adjusted to pH 6.5 with additional acid citrate dextrose, 10-8 M PGE, (final concentration) was added, and then the PRP was centrifuged at 1,500 g for 10 min. The plasma supernatant was decanted, 10 ,l of a solution containing 45 mg/ml creatine phosphate and 10 mg/ml creatine phosphokinase was added, and the platelet pellet was resuspended in 1 ml Hepes-Tyrode's buffer containing 130 mM NaCl, 9 mM sodium bicarbonate, 6 mM dextrose, 10 mM sodium citrate, 10 mM Trizma base, 3 mM KCl, 0.9 mM MgCl2, 2 mM Hepes, and 0.1% gelatin, pH 7.4, and also containing 10-8 M PGE1 (final concentration). The suspension of platelets (at -2 X 109 cells/ml) was incubated with 0.5 mCi of32PO4 at 37°C for 60 min, and then gel filtered through a Sepharose 2B column equilibrated and eluted with the HepesTyrode's buffer without PGEI. (14) . The gels were stained with 0.1 % Coomassie Brilliant Blue dye, destained, and the apparent molecular weights of the protein bands were determined by calibrating the gels with standard proteins of known molecular weight. Following autoradiography, the gels were sliced into 1-cm sections and dissolved by shaking in 0. After additions of plasmin, thrombin, or control buffer blank, the reacted platelet suspensions were pelleted by centrifugation at 8,700 g for 2 min, and radioactivity released into the supernatant was counted.
[32P] Phosphatidic acid production. Incubations of 32P04-labeled platelets were terminated by adding aliquots of the platelet suspensions to 3.75 vol chloroform/methanol (1:2). Lipids were extracted by a modified Bligh and Dyer procedure (16) . The lower chloroform fraction (pooled from three extractions) was evaporated under N2 and redissolved in chloroform/methanol (1:1) to be spotted for thin-layer chromatography (TLC). Boric acid-impregnated Whatman (Clifton, NJ) LK5 Linear K silica gel plates were activated at 1 10°C for 1 h and cooled prior to spotting. A TLC solvent system of chloroform/methanol/water/ammonium hydroxide (120:75:8:4) was used for resolution of acidic phospholipids (17) . Resolved lipids were visualized with 12 and autoradiography was performed as above. The band corresponding to phosphatidic acid was scraped, eluted with methanol, and 32p was determined by liquid scintillation spectroscopy.
[3H] Diglyceride production. Formation of [3H]diglyceride from platelet phospholipids labeled with [3H]arachidonic acid was measured as previously reported ( 18) .
Measurement ofcytosolic ionized cakium in platelets. Washed platelets were loaded with aequorin and quin2 as previously described (19) . Platelet counts were adjusted to 4 X 108/ml. In some experiments, aequorin luminescence and aggregation were measured simultaneously in the same sample using a modified Lumiaggregometer, as described previously (20) . Platelets were loaded with quin2-acetoxymethyl ester (quin2/ AM) to achieve an intracellular quin2 concentration of 1.0 to 1.6 mM. Measurement and calibration of aequorin and quin2 responses were as previously described (19) ; parallel control samples without aequorin or quin2 were treated similarly. The quin2 fluorescence signals were corrected for changes in autofluorescence of control samples.
Radioimmunoassay ofthromboxane B2 (TXB2). Platelets washed by gel filtration and suspended in Hepes-Tyrode's buffer were stimulated with plasmin or thrombin, as described below. The reactions were terminated at various time periods by adding aliquots to 3.75 vol chloroform/methanol (1:2). The methanol/H20 fractions from Bligh and Dyer extractions of these samples, containing TXB2, were evaporated under N2, resuspended in radioimmunoassay phosphate-gelatin buffer (50 mM potassium biphosphate, 0.14 M NaCl, and 0.1% gelatin, pH 6.8) and, following appropriate dilutions, the amount of TXB2 was determined by standard radioimmunoassay with radioimmunoassay buffer, a 1:2,000 dilution of TXB2 antiserum, and -10,000 cpm [3H]TXB2. After overnight incubation at 4°C, charcoal-coated dextran was used to separate antibody-bound from unbound radioligand. 
Results
The aggregation of washed platelets was induced by plasmin in a dose-dependent manner. As shown in Fig. 1 , partial aggregation was noted at 1.0 CU/ml and complete aggregation at 1.5 CU/ ml of plasmin, but the onset of aggregation following addition of plasmin was typically delayed even at the highest plasmin concentrations. Plasmin-induced aggregation was not inhibited by preincubation of the platelets with 0.5 mM aspirin for 30 min at 37°C (not shown).
Plasmin ( When 32P04 labeled platelets were incubated with various concentrations of plasmin for 1 min at 25°C, dose-dependent phosphorylation ofthe platelet 47,000-and 20,000-kD proteins was noted. Fig. 3 (left) shows an autoradiogram of the SDS-PAGE of a representative experiment. Fig. 3 (right) thrombin (1 U/ml) at 25°C is shown in Fig. 4 . Peak 32p04 incorporation into both proteins occurred in response to both plasmin and thrombin at 1 min, and this was followed by dephosphorylation. At 1 min, there was an -2.3-and 3.4-fold plasmin-stimulated increase over basal phosphorylation of the 20,000-and 47,000-kD proteins, respectively, and an -3. 1-and 3.7-fold thrombin-stimulated increase in phosphorylation of these respective proteins.
The plasmin-stimulated phosphorylation of the platelet 20,000-and 47,000-kD proteins was not affected by the extracellular [Ca2"]. As shown in Fig. 5 , the addition of 3 mM Ca2" to the medium did not increase the basal (lanes I and 3) or plasmin-stimulated (lanes 2 and 4) incorporation of32P04. Furthermore, 1 mM EGTA in the medium did not inhibit the plasmin-stimulated phosphorylation of either protein (lane 5). Elevation ofplatelet cyclic AMP inhibited protein phosphorylation in response to plasmin. Fig. 5 shows that preincubation ofplatelets for 5 min with 3 mM dibutyryl cyclic AMP (dBcAMP) completely blocked the plasmin-stimulated incorporation of 32p04 into both the 20,000-and 47,000-kD proteins (lane 7). Preincubation with 40 uM PGE, (lane 8) , an activator of platelet adenylate cyclase, resulted in 80 and 85% inhibition ofplasminstimulated phosphorylation of the 20,000-and 47,000-kD proteins, respectively. Preincubation of the platelets with 0.5 mM aspirin for 30 min at 37°C did not inhibit plasmin-induced phosphorylation (not shown).
Comparable patterns of protein phosphorylation were seen using plasmin from three different sources. As in the [14C]serotonin release experiments, alpha-2-antiplasmin completely blocked plasmin-induced protein phosphorylation but did not inhibit thrombin-induced protein phosphorylation. Hirudin blocked thrombin-induced phosphorylation but did not inhibit plasmin-induced phosphorylation.
The finding that plasmin stimulated platelet secretion and phosphorylation of the platelet myosin light chains and 47,000-kD protein suggested that its effects on platelets were mediated Fig. 6 also shows the response ofplatelets to thrombin (0.1 U/ml), a known platelet activator. Using either quin2 (Fig. 7) or aequorin (Fig. 8) obilization. In order to examine the effect of plasmin on the hydrolysis of endogenous platelet arachidonic acid by phospholipase(s), platelet membrane phospholipid pools were labeled with [3H]arachidonic acid and then stimulated with plasmin: the radioactivity released into the supernatant at various time intervals was then counted. As shown in Table I Fig. 9 , plasmin induced the rapid and transient production of diglyceride, followed by the generation of phosphatidic acid. In contrast to thrombin, which rapidly stimulated the formation of large amounts of thromboxane A2 (TXA2) in platelets, the production of TXA2 (measured by radioimmunoassay of TXB2) in response to 1.0 CU/ml plasmin was very small and markedly delayed (Table II) . Increasing the plasmin concentration up to 3.0 CU/ml did not enhance TXB2 production (data not shown).
Discussion
Synergistic interactions are known to occur between thrombin generation and platelet activation, which amplify and localize formation of the hemostatic plug at the site of vascular injury Changes in autofluorescence were subtracted or added to the quin2 signals before calibration as previously described (22). (21). Evidence is now accumulating to suggest that similar interactions may occur between plasmin and platelets to promote and localize clot lysis. Platelets actively contribute to fibrinolysis by serving as sites for the specific binding of plasminogen, accelerating the activation of plasminogen to plasmin (22) , and contributing to the regulation ofthe fibrinolytic system (23) (24) (25) (26) . Conversely, plasmin may also affect platelet function. Plasmin induces the loss ofplatelet membrane glycoprotein lb and thereby the ristocetin-mediated responsiveness ofplatelets to the adhesive protein, Factor VIII:von Willebrand factor (2) . Furthermore, we have recently reported that plasmin inhibits the reactivity of platelets to membrane-active agonists such as thrombin, collagen, and calcium ionophore (3). At higher concentrations, plasmin itself has been shown to directly induce platelet activation (27) (28) (29) . The present study was designed to investigate the biochemical mechanism of platelet stimulation by plasmin.
The results of this study suggest that plasmin stimulates platelet secretion through mechanisms involving activation of phospholipid dependent protein kinase C and possibly Ca21-calmodulin dependent protein kinases. It has been proposed that protein kinase C activation and Ca2" mobilization act synergistically to elicit a full biologic response (4), in this case platelet degranulation and aggregation. A marked delay is observed in the onset of plasmin-induced platelet aggregation ( Fig. 1) compared to the plasmin-induced initiation of secretion (Fig. 2) . Since interaction between fibrinogen and membrane fibrinogen receptors is required for the aggregation response of platelets, this discrepancy between aggregation and secretion is most readily explained by plasmin proteolysis of fibrinogen released from platelets and possibly also the plasmin cleavage of platelet fibrinogen receptors. We have demonstrated that plasmin can directly raise the platelet cytosolic Ca2" concentration. This was shown using shown that plasmin causes the formation of diacylglycerol and subsequently phosphatidic acid. It is of interest that although plasmin initiates inositol phospholipid turnover, there is very little thromboxane A2 (TXA2) produced. This could be due simply to the relatively low potency of plasmin as an activator of phospholipase C. However, there may also be an uncoupling of phospholipase C activation and arachidonic acid metabolism.
It has been previously shown that polymerization of actin in platelets stimulated by thrombin is required for the effective metabolism ofarachidonic acid released from phospholipids (33) , and it is possible that plasmin may degrade cytoskeletal proteins that are required to affect actin polymerization. The biologic response to plasmin in platelets is clearly not mediated by TXA2, since its formation is delayed well beyond the time that full plasmin-induced aggregation and release are attained. Furthermore, plasmin stimulated platelet aggregation and protein phosphorylation are unaffected by prior incubation with aspirin, which inhibits TXA2 production.
In summary, we have found that plasmin can act as a direct platelet agonist, stimulating platelet secretion by inducing an elevation in cytosolic Ca2'. This action of plasmin on platelets is associated with inositol phospholipid turnover and activation of protein kinase C. Plasmin stimulates maximal platelet protein phosphorylation to an extent comparable to that of thrombin, and plasmin is as potent a platelet secretagogue as thrombin. However, in its hemostatic actions plasmin is a weak agonist for platelets when compared with thrombin. Aggregation following exposure of platelets to plasmin is delayed and accompanied by the formation of only small amounts of the vasoconstrictor TXA2. In fact, plasmin at lower concentrations is a potent inhibitor of platelet aggregation and TXA2 production induced by thrombin (3) and it inhibits platelet adhesion by hydrolyzing platelet membrane glycoprotein lb (2) . Although circulating levels of plasmin approaching those causing these in vitro effects on platelets are theoretically attainable in vivo under pathologic or pharmacologic conditions, plasmin more likely exerts these actions on platelets locally at the site of clot formation where concentrations are probably amplified. The complex effects of plasmin on platelet function may play an important role in modulating dissolution of the hemostatic plug.
